NO961233L - Orale formuleringer av et antifungalt middel - Google Patents
Orale formuleringer av et antifungalt middelInfo
- Publication number
- NO961233L NO961233L NO961233A NO961233A NO961233L NO 961233 L NO961233 L NO 961233L NO 961233 A NO961233 A NO 961233A NO 961233 A NO961233 A NO 961233A NO 961233 L NO961233 L NO 961233L
- Authority
- NO
- Norway
- Prior art keywords
- antifungal agent
- oral formulations
- formulations
- oral
- antifungal
- Prior art date
Links
- 229940121375 antifungal agent Drugs 0.000 title 1
- 239000003429 antifungal agent Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12950493A | 1993-09-30 | 1993-09-30 | |
| PCT/EP1994/003169 WO1995008993A1 (en) | 1993-09-30 | 1994-09-22 | Oral formulations of an antifungal |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO961233D0 NO961233D0 (no) | 1996-03-27 |
| NO961233L true NO961233L (no) | 1996-03-27 |
| NO308985B1 NO308985B1 (no) | 2000-11-27 |
Family
ID=22440301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO961233A NO308985B1 (no) | 1993-09-30 | 1996-03-27 | Orale formuleringer av et antifungalt middel |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5707975A (no) |
| EP (1) | EP0721337B1 (no) |
| JP (1) | JP3034048B2 (no) |
| CN (1) | CN1086579C (no) |
| AP (1) | AP630A (no) |
| AT (1) | ATE209916T1 (no) |
| AU (1) | AU692180B2 (no) |
| CA (1) | CA2170622C (no) |
| CY (1) | CY2272B1 (no) |
| CZ (1) | CZ288026B6 (no) |
| DE (1) | DE69429359T2 (no) |
| DK (1) | DK0721337T3 (no) |
| ES (1) | ES2169087T3 (no) |
| FI (1) | FI115443B (no) |
| HU (1) | HU221632B1 (no) |
| IL (1) | IL111093A (no) |
| MY (1) | MY111136A (no) |
| NO (1) | NO308985B1 (no) |
| NZ (1) | NZ273619A (no) |
| OA (1) | OA10276A (no) |
| PH (1) | PH31594A (no) |
| PL (1) | PL313731A1 (no) |
| PT (1) | PT721337E (no) |
| RO (1) | RO115114B1 (no) |
| RU (1) | RU2118899C1 (no) |
| SG (1) | SG48826A1 (no) |
| SK (1) | SK282627B6 (no) |
| TW (1) | TW349870B (no) |
| WO (1) | WO1995008993A1 (no) |
| ZA (1) | ZA947619B (no) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000509374A (ja) | 1996-04-19 | 2000-07-25 | アルファ セラピュティック コーポレイション | 凍結乾燥した血液タンパク質のウイルス不活性化方法 |
| US20020052390A1 (en) | 1997-10-22 | 2002-05-02 | Jens Ponikau | Methods and materials for treating and preventing inflammation of mucosal tissue |
| US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| US6231875B1 (en) * | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
| ES2157731B1 (es) * | 1998-07-21 | 2002-05-01 | Liconsa Liberacion Controlada | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
| ATE307808T1 (de) | 1999-03-24 | 2005-11-15 | Scherer Technologies Inc R P | Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser |
| PL198797B1 (pl) | 1999-03-31 | 2008-07-31 | Janssen Pharmaceutica Nv | Zastosowanie wstępnie żelowanej skrobi |
| AU5975700A (en) * | 1999-07-02 | 2001-01-22 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
| CA2291346A1 (en) | 1999-11-26 | 2001-05-26 | Bernard Charles Sherman | Antifungal solutions |
| US6932861B2 (en) | 2000-11-28 | 2005-08-23 | Fmc Corporation | Edible PGA coating composition |
| US6673373B2 (en) | 2001-02-01 | 2004-01-06 | Carlsbad Technology Inc. | Antifungal formulation and the methods for manufacturing and using the same |
| WO2002072102A1 (en) * | 2001-03-05 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Taste masked liquid pharmaceutical compositions |
| CA2363376A1 (en) * | 2001-11-16 | 2003-05-16 | Bernard Charles Sherman | Solid pharmaceutical compositions for oral administration comprising itraconazole |
| US20050025791A1 (en) * | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
| US7446107B2 (en) * | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| WO2003074474A2 (en) * | 2002-03-01 | 2003-09-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
| RU2205644C1 (ru) * | 2002-02-18 | 2003-06-10 | Акционерное Курганское общество медицинских препаратов и изделий "Синтез" | Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения |
| US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| CN1255105C (zh) * | 2002-12-17 | 2006-05-10 | 上海医药工业研究院 | 齐拉西酮及其盐的水溶性包合物及其制备方法 |
| US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| CA2440172C (en) * | 2003-09-05 | 2011-01-11 | Bernard Charles Sherman | Itraconazole solution |
| US20050074494A1 (en) * | 2003-10-06 | 2005-04-07 | Xiu-Xiu Cheng | Itraconazole immediate release formulation |
| US20050118265A1 (en) * | 2003-11-28 | 2005-06-02 | Anandi Krishnan | Antifungal oral dosage forms and the methods for preparation |
| CN1889943A (zh) * | 2003-12-08 | 2007-01-03 | 美国亚利桑那大学董事会 | 协同抗癌组合物 |
| GR1005154B (el) * | 2005-02-09 | 2006-03-13 | Verisfield (Uk) Ltd. | Σταθερες φαρμακευτικες συνθεσεις ιτρακοναζολης σευδατικο περιβαλλον |
| CA2615799A1 (en) * | 2005-07-21 | 2007-02-01 | Nomir Medical Technologies, Inc. | Near infrared microbial elimination laser system (nimels) |
| US20070082870A1 (en) * | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| TWI448285B (zh) * | 2006-07-13 | 2014-08-11 | Los Angeles Biomed Res Inst | 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法 |
| CN102114002B (zh) | 2006-12-04 | 2016-05-11 | 苏佩努斯制药公司 | 托吡酯的增强的立即释放制剂 |
| US8906647B2 (en) | 2008-02-21 | 2014-12-09 | Sequoia Pharmaceuticals, Inc. | Diamide inhibitors of cytochrome P450 |
| US20100009009A1 (en) | 2008-07-10 | 2010-01-14 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
| US20100233101A1 (en) | 2009-02-13 | 2010-09-16 | Micropure, Inc. | Composition and method for the oxidative consumption of salivary biomolecules |
| US20120093828A1 (en) | 2009-03-19 | 2012-04-19 | Ibrahim Ashraf S | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases |
| RU2618456C2 (ru) * | 2010-12-16 | 2017-05-03 | Плэтформ Брайтворкс Ту, Лтд | Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям |
| CN102670490A (zh) * | 2012-05-10 | 2012-09-19 | 南京特丰药业股份有限公司 | 一种伊曲康唑口服溶液及其制备方法 |
| CN103230363A (zh) * | 2013-03-29 | 2013-08-07 | 湖北凤凰白云山药业有限公司 | 一种抗真菌的口服溶液 |
| CA3020197C (en) | 2017-09-01 | 2024-06-04 | Micropure, Inc. | Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions |
| RU2707286C1 (ru) * | 2019-07-02 | 2019-11-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | Фармацевтическая противогрибковая композиция на основе производного хлорфенилбутандиона и способ её получения |
| CN114191386B (zh) * | 2021-12-26 | 2024-03-12 | 苏州海景医药科技有限公司 | 一种波生坦口服溶液的制备方法 |
| CN114191387A (zh) * | 2021-12-26 | 2022-03-18 | 苏州海景医药科技有限公司 | 一种伏立康唑口服液的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4863737A (en) * | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US4883785A (en) * | 1984-07-27 | 1989-11-28 | Chow Wing Sun | Complex of anti-fungal agent and cyclodextrin and method |
| GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| US4870060A (en) * | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
| US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| DE68900991D1 (de) * | 1988-01-29 | 1992-04-23 | Sankyo Co | Cyclosporin-zusammensetzungen. |
| SU1708343A1 (ru) * | 1989-09-22 | 1992-01-30 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Способ получени твердых лекарственных форм |
| HU221189B1 (en) * | 1992-03-18 | 2002-08-28 | Janssen Pharmaceutica Nv | Itraconazole and saperconazole stereoisomers, their cyclodextrin complexes and pharmaceutical compositions containing them and process for producing them |
-
1994
- 1994-09-08 TW TW083108274A patent/TW349870B/zh not_active IP Right Cessation
- 1994-09-08 PH PH48937A patent/PH31594A/en unknown
- 1994-09-22 SK SK399-96A patent/SK282627B6/sk not_active IP Right Cessation
- 1994-09-22 DE DE69429359T patent/DE69429359T2/de not_active Expired - Lifetime
- 1994-09-22 PL PL94313731A patent/PL313731A1/xx unknown
- 1994-09-22 US US08/604,950 patent/US5707975A/en not_active Expired - Lifetime
- 1994-09-22 CA CA002170622A patent/CA2170622C/en not_active Expired - Lifetime
- 1994-09-22 AT AT94927639T patent/ATE209916T1/de active
- 1994-09-22 PT PT94927639T patent/PT721337E/pt unknown
- 1994-09-22 WO PCT/EP1994/003169 patent/WO1995008993A1/en not_active Ceased
- 1994-09-22 EP EP94927639A patent/EP0721337B1/en not_active Expired - Lifetime
- 1994-09-22 AU AU76979/94A patent/AU692180B2/en not_active Expired
- 1994-09-22 DK DK94927639T patent/DK0721337T3/da active
- 1994-09-22 HU HU9600804A patent/HU221632B1/hu unknown
- 1994-09-22 CN CN94193602A patent/CN1086579C/zh not_active Expired - Lifetime
- 1994-09-22 RO RO96-00673A patent/RO115114B1/ro unknown
- 1994-09-22 RU RU96108776A patent/RU2118899C1/ru active
- 1994-09-22 JP JP7510099A patent/JP3034048B2/ja not_active Expired - Lifetime
- 1994-09-22 NZ NZ273619A patent/NZ273619A/en not_active IP Right Cessation
- 1994-09-22 CZ CZ1996823A patent/CZ288026B6/cs not_active IP Right Cessation
- 1994-09-22 SG SG1996002179A patent/SG48826A1/en unknown
- 1994-09-22 AP APAP/P/1996/000792A patent/AP630A/en active
- 1994-09-22 ES ES94927639T patent/ES2169087T3/es not_active Expired - Lifetime
- 1994-09-28 MY MYPI94002583A patent/MY111136A/en unknown
- 1994-09-29 IL IL11109394A patent/IL111093A/en not_active IP Right Cessation
- 1994-09-29 ZA ZA947619A patent/ZA947619B/xx unknown
-
1996
- 1996-03-27 NO NO961233A patent/NO308985B1/no not_active IP Right Cessation
- 1996-03-29 FI FI961436A patent/FI115443B/fi not_active IP Right Cessation
- 1996-03-29 OA OA60806A patent/OA10276A/en unknown
-
2002
- 2002-05-15 CY CY0200025A patent/CY2272B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO961233D0 (no) | Orale formuleringer av et antifungalt middel | |
| LU90115B1 (fr) | Formulation orale de 2-méthyl-thiéno-benzodiazépine | |
| DE69518331D1 (de) | Orale zubereitungen | |
| PT769965E (pt) | Formulacoes aquosas de risperidona | |
| DE69321461D1 (de) | Desinfizierende zusammensetzung | |
| FI955144A0 (fi) | Päällystetyt farmaseuttiset koostumukset | |
| NO962490D0 (no) | Orale formuleringer av S(+)-ibuprofen | |
| FI950402L (fi) | Oraaliset koostumukset | |
| NO962491D0 (no) | Orale formuleringer av S(+)-etodolac | |
| EP0836470A4 (en) | ORAL COMPOSITIONS | |
| ATA181095A (de) | Probiotisch wirksame formulierung | |
| ATE263550T1 (de) | Orale cyclosporinformulierungen | |
| IT1276799B1 (it) | Formulazioni di f-silicone | |
| DE69626898D1 (de) | Strahlungsempfindliche Zusammensetzung | |
| ITMI920393A1 (it) | Formulazioni di steroidi | |
| DE69300492D1 (de) | Orale Zusammensetzung. | |
| ITMI950379A0 (it) | Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico | |
| EP0837863A4 (en) | DISODIUM ALENDRONATE PREPARATIONS | |
| DE69430362D1 (de) | Ektoparasitizide formulierung | |
| DE69225990D1 (de) | Lichtempfindliche Bistrihalomethyl-s-triazin-Verbindung und photopolymerisierbare Zusammensetzung, dieselbe enthaltend | |
| DE69413539D1 (de) | Orale brausezusammensetzungen | |
| EE9700123A (et) | Välispidiselt kasutatav põletikuvastane vahend | |
| NO944839D0 (no) | Anvendelse av vismut | |
| ITMI950380A0 (it) | Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico | |
| ITRM920116A0 (it) | Formulazioni liposomiche di piroxicam. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |